At the transporter–immune axis, LAT1 inhibition reduces PD-L1 expression in NSCLC cells [220], while xCT blockade disrupts glutathione homeostasis and supports combination with checkpoint blockade [229]. Here, SLC7A11 is linked to non-small cell lung carcinoma.